found a polyclonal CD8+ T cell response to mutant KRASG12D from tumor infiltrating lymphocytes obtained from a patient with metastatic colorectal cancer, and infused HLA-C*08:02-restricted recombinant TCR-T cells targeting KRASG12D into the patient, and observed the objective regression of the tumor (41). Here, CD8A is linked to neoplasm.